CMND-100

June 22, 2026: Clearmind Medicine Inc. (NASDAQ: CMND) announced it has successfully completed treatment for all participants in Part A of its ongoing Phase I/II clinical trial of CMND-100 for Alcohol Use Disorder (AUD). All 24 participants across Cohorts 1–4 completed treatment per protocol. The company said it is now assessing the dataset and, if results remain favorable, intends to initiate the next stage of its clinical program in AUD patients. The multicenter trial is conducted under FDA oversight at sites in the U.S. and Israel, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. No efficacy or safety results were provided in the release.